Study participants, inclusion and exclusion criteria
hookworm infection, allergic reaction
HOOKWORM, HOOKWORM INFECTION, ALLERGIC REACTION
In Mayuge district, primary four (P4) and primary five (P5) students aged 8–16 years were the target population for the prevalence survey in January and February 2022. Target schools were selected with probability proportional to school size and an equal number of students from each selected school were invited to participate. English and Lusoga (the local language in Mayuge district) versions of the consent form and child assent form were used.Among children who were detected as having hookworm infection in the prevalence survey in January and February 2022, randomly selected hookworm positive students were invited to participate in a randomised controlled trial to assess the impact of dual- vs single-dose albendazole and the impact of co-administration with avocado (a fatty food) versus no co-administration with avocado, on hookworm cure rate and egg reduction rate.Trial inclusion criteria wereChild identified with hookworm infection in the January and February 2022 prevalence surveyChild attending randomly selected P4 and P5 classes in one of the randomly selected schoolsChild signed the child assent form and whose parents/guardian provide written informed consent for the prevalence survey and for the nested trial if hookworm infection was detected.Trial exclusion criteria were:Child who received benzimidazole drugs such as albendazole and mebendazole within three months before the prevalence survey, to avoid the residual effect of previously administrated drugs.Child who had a history of allergic reaction to any benzimidazole drugs such as mebendazole.